Moderna

Moderna. It is an American pharmaceutical and biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. Founded in 2010, the company rose to global prominence during the COVID-19 pandemic with the rapid development and authorization of its mRNA-1273 vaccine, marketed as Spikevax. Moderna's platform technology is designed to instruct cells to produce proteins that can prevent or fight disease, with applications spanning infectious diseases, oncology, and rare diseases.

History

The company was co-founded in September 2010 by venture capitalist Noubar Afeyan, renowned MIT professor Robert Langer, Harvard scientist Kenneth R. Chien, and stem cell biologist Derrick Rossi, based on Rossi's groundbreaking work in modified mRNA. Initially named ModeRNA Therapeutics, it launched with one of the largest-ever biotech initial public offerings in 2018, raising over $600 million on the Nasdaq. Its research was significantly accelerated by partnerships with agencies like the National Institutes of Health and the Biomedical Advanced Research and Development Authority. The declaration of a global pandemic by the World Health Organization in March 2020 catalyzed an unprecedented effort, leading to the Emergency Use Authorization of its COVID-19 vaccine by the U.S. Food and Drug Administration in December 2020, a milestone achieved in collaboration with the National Institute of Allergy and Infectious Diseases under Anthony Fauci.

Technology and platform

At its core, Moderna's approach utilizes synthetic messenger RNA to direct cells to produce specific proteins, effectively turning the body's own cellular machinery into a drug factory. This technology relies on key innovations in nucleotide chemistry to enhance stability and reduce unwanted immune response. The company's platform encompasses a suite of proprietary technologies, including its lipid nanoparticle delivery system, which encapsulates and protects the mRNA for efficient delivery into human cells. This modular platform allows for rapid design and development, as demonstrated by the swift creation of vaccine candidates for emerging variants like Omicron and other pathogens such as respiratory syncytial virus and influenza. Research and development activities are centralized at its facilities in Cambridge, Massachusetts, and it maintains strategic manufacturing partnerships with firms like Lonza Group.

Products and pipeline

The company's first commercially approved product is its mRNA-1273 COVID-19 vaccine, sold under the brand name Spikevax, which has received authorization or approval in numerous countries including the United States, the European Union, and the United Kingdom. Its clinical pipeline is extensive, with over 40 development programs. In infectious diseases, this includes advanced candidates for a combined COVID-19 and influenza vaccine, a vaccine for cytomegalovirus, and an Epstein–Barr virus vaccine. In oncology, the pipeline features personalized cancer vaccines developed in collaboration with Merck & Co. targeting conditions like melanoma. Additional therapeutic areas include rare diseases, such as programs for propionic acidemia and methylmalonic acidemia, and cardiovascular disease treatments. The company is also advancing vaccines for public health threats like Zika virus and Nipah virus.

Corporate affairs

The company is led by Chief Executive Officer Stéphane Bancel and chaired by co-founder Noubar Afeyan. It is a publicly traded entity, listed on the Nasdaq Global Select Market under the ticker symbol MRNA and is a component of both the Nasdaq-100 and the S&P 500 indices. Its corporate headquarters and main research labs are located in Cambridge, Massachusetts, with a significant manufacturing presence expanded during the pandemic. Major strategic alliances and funding have come from organizations like the Coalition for Epidemic Preparedness Innovations and the U.S. Department of Defense. The company has engaged in numerous technology licensing agreements and patent cross-licenses, particularly concerning its foundational mRNA intellectual property.

Controversies and legal issues

The company has faced several disputes, most notably protracted intellectual property battles with rivals like BioNTech and Pfizer over patents related to mRNA vaccine technology, with lawsuits filed in courts including the United States District Court for the District of Massachusetts and the European Patent Office. It has also been criticized for the pricing of its COVID-19 vaccine and its initial reluctance to share technical know-how with the World Health Organization's mRNA vaccine technology transfer hub to boost global manufacturing. Further scrutiny has involved its contractual arrangements with governments, such as those with the European Commission, and allegations related to the transparency of its clinical trial data. The rapid scale-up of its operations and its significant financial gains during the pandemic have also attracted attention from policymakers and public health advocates worldwide.

Category:Biotechnology companies of the United States Category:Pharmaceutical companies of the United States Category:Companies based in Cambridge, Massachusetts Category:Companies listed on the Nasdaq